The slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence

Data Supplement

• Supplemental Data -

  Supplemental Figure 1 - LY2828360 displays a delayed signaling profile at human CB2 receptors

  Supplemental Figure 2 - LY2828360 failed to affect IP1 levels through either mouse or human CB2 receptors